|
|
3M-052-Alum |
|
Vaxjo ID |
141 |
|
Vaccine Adjuvant Name |
3M-052-Alum |
|
Adjuvant VO ID |
VO_0005387
|
|
Description |
mineral salt, compound adjuvant of synthetic derivative of natural compound with TLR7 and TLR8 receptors, induce th1 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
United States |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
3M-052 |
|
Storage |
2-8C |
|
Preparation |
For clinical uses, 3M-052-Alum is formulated by using 3M-052-AF with an antigen adsorbed to Alum. |
|
Function |
Type: mineral salt vaccine adjuvant. Target Receptor: Toll-like receptor 7 (TLR7) | Toll-like receptor 8 (TLR8). Induces Th1-biased immune profile. innate immune activation |
| References |
(Soza, 2025): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=59]
Fox et al., 2016: Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG. Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. Journal of controlled release : official journal of the Controlled Release Society. 2016; 244(Pt A); 98-9107. [PubMed: 27847326].
Hahn et al., 2024: Hahn WO, Parks KR, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, Woodward Davis AS, Duplessis C, Tomai M, Dey AK, Sagawa ZK, De Rosa SC, Seese A, Kallur Siddaramaiah L, Stamatatos L, Lee WH, Sewall LM, Karlinsey D, Turner HL, Rubin V, Furth S, MacPhee K, Duff M, Corey L, Keefer MC, Edupuganti S, Frank I, Maenza J, Baden LR, Hyrien O, Sanders RW, Moore JP, Ward AB, Tomaras GD, Montefiori DC, Rouphael N, McElrath MJ. Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies. The Journal of experimental medicine. 2024; 221(10); . [PubMed: 39235529].
|
|
